A client with liver cirrhosis is experiencing episodes of hepatic encephalopathy. Which medication should the nurse anticipate administering to help reduce ammonia levels in the blood?

A) Hemochromatosis is a genetic disorder characterized by excessive iron absorption from the diet, leading to the accumulation of iron in various organs, including the liver. In individuals with hemochromatosis, the excess iron can cause liver cell injury and lead to cirrhosis over time.

B) Wilson's disease is a genetic disorder that causes impaired copper metabolism, leading to copper accumulation in the liver and other organs. While it can lead to liver damage, it is not associated with elevated iron levels.

C) Alpha-1 antitrypsin deficiency is a genetic disorder that affects the lungs and liver. It can lead to liver disease, but it does not cause elevated iron levels.

D) Primary biliary cholangitis is an autoimmune liver disease that primarily affects the small bile ducts within the liver. While it can lead to liver damage and cirrhosis, it is not associated with elevated iron levels.

A) Spironolactone is a potassium-sparing diuretic commonly used to manage fluid retention in liver cirrhosis. The nurse should monitor the client's serum potassium levels regularly as this medication can cause hyperkalemia (elevated potassium levels). It is important to assess potassium levels to avoid complications associated with imbalances in potassium levels.

B) Monitoring blood glucose levels is not specifically related to the use of spironolactone in liver cirrhosis. Spironolactone does not have a significant effect on blood glucose levels.

C) Monitoring the white blood cell count is not directly related to the use of spironolactone. White blood cell count is typically monitored to assess for signs of infection or immune system response.

D) Monitoring serum calcium levels is not directly related to the use of spironolactone in liver cirrhosis. Spironolactone does not significantly impact calcium levels in the blood.